Sunday, November 8, 2026

USD/CNH Falls By 2% In The Last 21 Sessions

ViaNews Editorial Team

November 30, 2023

USD/CNH Falls By 2% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.44% for the last 21 sessions. At 02:13 EST on Thursday, 30 November, USD/CNH (USDCNH) is $7.14.

USD/CNH's yearly highs and lows, it's 0.422% up from its 52-week low and 0.06% down from its 52-week high.

News about

  • Eur/usd remains capped below 1.0950, eyes on eurozone inflation, US GDP data. According to FXStreet on Monday, 27 November, "The downside risks to growth in Germany, Europe's largest economy might exert some selling pressure on the Euro (EUR) and act as a headwind for the EUR/USD pair. "
  • Eur/usd forex signal: euro has more upside ahead - 27 November 2023. According to DailyForex on Monday, 27 November, "The EUR/USD exchange rate has been in a strong bullish trend in the past few days. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bullish viewBuy the EUR/USD pair and set a take-profit at 1.1040."
  • According to FXStreet on Monday, 27 November, "Further north, EUR/USD might face resistance around the August top of 1.1064 (August 10) and another weekly peak of 1.1149 (July 27), all preceding the 2023 high of 1.1275 (July 18)."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
USD/CNH Falls By 2% In The Last 21 Sessions | Via News